Check 35,000+ stocks against 26 valuation models and 37 quality factors

Caplin Point Laboratories Limited (524742) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Caplin Point Laboratories Limited ₹2,445, price ₹2,632, upside -7.1%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · IN · ISIN INE475E01026

CP Thin data Sep 24, 2026

Caplin Point Laboratories Limited

524742 · BSE

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value ₹2,445 · Fairly valued (−7.1%)

✓Quality 63/100

!Mixed Growth (revenue 5y +17.6 %/yr)

✓Highly profitable · 23.0% net margin (TTM)

✓Low debt

✓0.5% dividend yield · Well covered

✓Wide moat 81/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear ₹1,220 to bull ₹3,887 Growth analysisrevenue history, year by year Quality 63/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Caplin Point Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹576.79 – ₹2,866 · fair‑value band ₹1,220 – ₹3,887 · the ₹2,632 price screens above the ₹2,445 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally.

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, vials, ophthalmic products, liquid orals, soft gel capsules, ointments, creams and gels, powder for injections, suppositories and ovules, dermo cosmetics, surgicals and disposables, pre-mix bag formulations, inhalers and sprays, IV infusion products, dry syrups, topicals, and other products, as well as liquid, lyophilized, and pre-filled injection syringes. The company also operates QueTenX, an e-commerce website. Caplin Point Laboratories Limited was founded in 1990 and is based in Chennai, India.

Stock analysis

Caplin Point Laboratories Limited (524742) currently trades at ₹2,632, while our model-based Fair Value estimate is ₹2,445, so the stock looks roughly fairly valued today (gap 7.7%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹2,043 per share, and 1 of the 26 models we run sit above the ₹2,632 price.

Bear case: the Asset-Based group reads lowest at ₹252.48, and 25 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹1,220 (bear) to ₹3,887 (bull), the price of ₹2,632 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Caplin Point Laboratories Limited reported revenue of ₹19.4B in FY2025 versus ₹10.6B in FY2021, a compound +16.2%/yr. Reported net income was ₹5.4B in FY2025, compounding +22.0%/yr from FY2021.

Key figures

Market cap ₹40.0B (≈ $416M) · P/E ratio 16.9 · P/S ratio 4.68 · EPS (TTM) ₹28.71 · Dividend yield 0.5% · Net margin 27.7% · Return on equity 24.4% · Return on assets (EBIT) 19.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −7%, 524742 screens cheaper than that median.

Fair Value models

Bear ₹1,220 Fair Value ₹2,445 Bull ₹3,887

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹26.21 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ₹432.44 ₹650.49 ₹1,246 77

Growth DCF ₹409.73 ₹691.64 ₹1,184 75

EPV ₹574.56 ₹650.48 ₹713.75 74

All 26 models by family

DCF Models

FCF DCF ₹432.44 ₹650.49 ₹1,246 77

Owner Earnings ₹709.76 ₹1,452 ₹2,829 72

5Y Revenue Exit ₹528.35 ₹985.01 ₹1,888 68

5Y EBITDA Exit ₹741.75 ₹1,441 ₹2,739 71

5Y P/E Exit ₹915.48 ₹2,028 ₹3,489 67

10Y Revenue Exit ₹470.24 ₹997.25 ₹1,583 64

10Y EBITDA Exit ₹627.19 ₹1,374 ₹2,783 63

10Y P/E Exit ₹739.72 ₹1,680 ₹3,358 59

Earnings-Based

Graham-Dodd ₹482.12 ₹3,362 ₹4,718 63

Lynch FV ₹1,039 ₹1,485 ₹1,930 61

PEG = 1.0 ₹1,039 ₹1,485 ₹1,930 57

EPV ₹574.56 ₹650.48 ₹713.75 74

Dividend Discount

Gordon GGM ₹39.02 ₹70.31 ₹96.79 68

DDM Multi-Stage ₹39.02 ₹64.23 ₹75.11 67

Multiples

P/E Multiple ₹1,170 ₹1,560 ₹1,950 63

P/S Multiple ₹672.35 ₹896.47 ₹1,121 58

P/B Multiple ₹903.98 ₹1,205 ₹1,507 55

EV/EBIT ₹1,004 ₹1,332 ₹1,661 66

EV/EBITDA ₹921.30 ₹1,222 ₹1,524 67

EV/Revenue ₹555.69 ₹786.21 ₹1,017 54

Asset-Based

NCAV (Graham) ₹188.42 ₹252.48 ₹376.84 54

Growth DCF

Growth DCF ₹409.73 ₹691.64 ₹1,184 75

Rev-Margin DCF ₹528.35 ₹1,062 ₹1,870 69

Economic Profit

Residual Income ₹403.00 ₹565.17 ₹992.49 73

ROIC Compounder ₹678.40 ₹932.30 ₹1,180 72

Growth Earnings

Growth-Adj P/E ₹1,430 ₹2,043 ₹2,656 67

Open the full fair value analysis →

Notify me when 524742 reaches fair value

Put 524742 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 62 · Market factors (momentum, volatility) 67

Profitability 73

Margins and returns on capital today

Quality Growth 57

Are margins and returns improving?

Cashflow 44

Earnings quality: real cash, not paper profit

Fin. Strength 83

Balance sheet, leverage, solvency risk

Investment 19

Disciplined investing over empire-building

Low Volatility 65

Calm price path (market factor)

Momentum 69

Price trend over the last 3–12 months (market factor)

52W Momentum 66

Distance to the 52-week high (market factor)

Net Issuance 81

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 91/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+14.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+15.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.6%

Start year 2020 (pandemic). Over 10 years: +22.6% a year

Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+24.6%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+20.4%

Earnings growth per share plus dividend.

Earnings per share, growth per year+19.9%

Dividend (yield on the price)0.5%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 30%

Watch 524742, get fair value alerts →

Compare Caplin Point Laboratories Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 8/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 63 · Above median

Fair Value upside −47.3% · Below median

Profitability

Return on equity (TTM) 24.4% · Top 25%

Return on assets 14.0% · Top 25%

Net margin (TTM) 23.0% · Top 25%

Operating margin (TTM) 25.9% · Top 25%

Growth and dividend

Revenue growth 18.0% · Above median

Dividend yield (TTM) 0.5% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 16.9× · Cheaper than median

P/B 1.40× · Cheaper than median

P/S (TTM) 4.20× · Priciest 25%

EV/EBITDA 13.8× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Caplin Point Laboratories Limited · Fair Value
₹2,445 −7%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/524742" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Caplin Point Laboratories Limited · Fair Value</span><br><b style="font-size:20px">₹2,445</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−7%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Caplin Point Laboratories Limited Fair Value". https://www.fairvalue-calculator.com/stock/524742

Frequently asked questions

Is Caplin Point Laboratories Limited (524742) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ₹2,445 versus a price of ₹2,632, about −7% upside (fairly valued).

What is the fair value of 524742?

Our model-based fair value for Caplin Point Laboratories Limited is ₹2,445 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹2,632.

What is the quality score of 524742?

Caplin Point Laboratories Limited has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Caplin Point Laboratories Limited (524742)?

Our model-based price target is the fair value of ₹2,445 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹1,220, optimistic scenario ₹3,887. It is a calculation from audited fundamentals, not an analyst target.

What is the Caplin Point Laboratories Limited stock forecast for 2026?

Our models put fair value at ₹2,445, about −7% upside versus a price of ₹2,632 (fairly valued). Cautious scenario ₹1,220, optimistic scenario ₹3,887. The calculation is refreshed regularly with new filings.

What is the revenue of Caplin Point Laboratories Limited (524742)?

Caplin Point Laboratories Limited reported trailing-twelve-month revenue of about ₹9.5B (latest available figure, as of Sep 24, 2026).

Does Caplin Point Laboratories Limited pay a dividend?

Caplin Point Laboratories Limited currently shows a dividend yield of about 0.52% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Caplin Point Laboratories Limited (524742)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caplin Point Laboratories Limited it is ₹2,445 per share (as of Sep 24, 2026), against a price of ₹2,632. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Caplin Point Laboratories Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 524742 trades above its calculated fair value: price ₹2,632, fair value ₹2,445, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 524742?

No. The price is what the market pays today (₹2,632); the fair value is what the company's own numbers justify (₹2,445). For Caplin Point Laboratories Limited the two are ₹187.43 per share apart. That gap is exactly why we show both numbers side by side.

How much is Caplin Point Laboratories Limited worth?

The market values Caplin Point Laboratories Limited at about ₹40.0B (market capitalisation, as of Sep 24, 2026). Per share that is ₹2,632; our models calculate a fair value of ₹2,445 per share.

What do the bullish and bearish scenarios say about 524742?

Our models span a range for Caplin Point Laboratories Limited: cautious scenario ₹1,220, base ₹2,445, optimistic ₹3,887 per share (as of Sep 24, 2026, price ₹2,632). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 524742?

Caplin Point Laboratories Limited trades at a price-to-earnings ratio of 16.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,445 is built from several models across several years. Other multiples: P/B 1.4, P/S 4.2, EV/EBITDA 13.8.

How solid is the balance sheet of Caplin Point Laboratories Limited (524742)?

Balance-sheet figures for Caplin Point Laboratories Limited (as of Sep 24, 2026): return on equity 24.4%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.

How far is 524742 from its 52-week high?

Caplin Point Laboratories Limited trades at ₹2,632, about 8% below its 52-week high of ₹2,866 and 75% above the low of ₹1,502 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,445 is for.

Which stocks are comparable to Caplin Point Laboratories Limited?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Caplin Point Laboratories Limited stock attractive at the current price?

The data as of Sep 24, 2026: price ₹2,632, calculated fair value ₹2,445 (−7%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 524742 calculated?

We run Caplin Point Laboratories Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2,445, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Caplin Point Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Caplin Point Laboratories Limited (524742)?

The closing price on Oct 1, 2026 was ₹2,632. Our model-based fair value is ₹2,445, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Caplin Point Laboratories Limited right now?

The model range is unusually wide (₹1,220 to ₹3,887). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Caplin Point Laboratories Limited

How large is the market capitalisation of Caplin Point Laboratories Limited (524742)?

The market capitalisation of Caplin Point Laboratories Limited is ₹40.0B (≈ $416M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Caplin Point Laboratories Limited (524742)?

The price-to-sales ratio of Caplin Point Laboratories Limited is 4.68 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Caplin Point Laboratories Limited (524742)?

Earnings per share at Caplin Point Laboratories Limited are ₹28.71 (price ÷ EPS = P/E 16.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Caplin Point Laboratories Limited (524742)?

The dividend yield of Caplin Point Laboratories Limited is 0.5% (payout 47.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Caplin Point Laboratories Limited (524742)?

The net margin of Caplin Point Laboratories Limited is 27.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Caplin Point Laboratories Limited (524742)?

The return on equity (ROE) of Caplin Point Laboratories Limited is 24.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Caplin Point Laboratories Limited (524742)?

On an EBIT basis the return on assets of Caplin Point Laboratories Limited is 19.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Caplin Point Laboratories Limited (524742)?

The operating margin of Caplin Point Laboratories Limited is 25.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Caplin Point Laboratories Limited (524742)?

Revenue at Caplin Point Laboratories Limited is growing +18.0% versus a year earlier (3y avg +15.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Caplin Point Laboratories Limited (524742)?

Earnings per share at Caplin Point Laboratories Limited are growing −0.7% versus a year earlier. How much earnings per share grew versus a year earlier.

Free · no account needed

Watch Caplin Point Laboratories Limited in the live analysis

One click puts Caplin Point Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.